Introduction {#s1}
============

Selective serotonin reuptake inhibitors (SSRI) are the most prescribed medications for major depressive episodes ([@bib6]). The effects of SSRI on improving mood and reducing anxiety have been well documented ([@bib61]; [@bib56]; [@bib9]) and many experimental studies showed that serotonin modulates emotional processing even in healthy volunteers ([@bib36]; [@bib54]). Loss of interest or pleasure in daily activities is also a key symptom of depression ([@bib1]). However, the impact of SSRI on the motivation deficit (apathy) remains rather controversial ([@bib48]; [@bib64]).

Indeed, several studies reported that SSRI treatments do not reduce apathy as much as other symptoms ([@bib28]) or can even *induce* apathy in patients ([@bib5]; [@bib51]; [@bib46]). However, other studies also reported that SSRI treatments increase motivation or at least the sensitivity to reward ([@bib59]; [@bib58]; [@bib67]). The related animal literature is also contradictory: some studies on cost/benefit trade-off showed reduced effort expenditure with SSRIs ([@bib66]) or no effect with serotonin blockers ([@bib23]), while other studies reported increased motor activity induced by SSRI ([@bib64]) or optogenetic stimulation of the dorsal raphe nucleus ([@bib62]).

One issue with clinical studies is that SSRI effects may be confounded by an interaction with the pathological state: an SSRI treatment was reported to decrease apathy in late-life depression ([@bib67]) and to increase it in Parkinson's disease ([@bib68]). Another issue is that apathy may not be a simple construct. It is typically captured as a loss of behavioral activation ([@bib11]; [@bib60]), which could arise from different causes at the cognitive level: for instance a diminished sensitivity to reward attractiveness, or alternatively an exacerbated sensitivity to action cost. The ambition of the present study therefore was two-fold: we aimed (1) to clarify the effects of an SSRI on the motivation of effortful behavior in healthy volunteers, unconfounded by psychopathology, and (2) to reconcile these effects with a more general role of serotonin in the sensitivity to action costs vs. benefits.

Although experimental findings seem diverse at first sight, they might suggest a general role for serotonin in the behavioral adaptation to action costs. Previous studies suggested that serotonin is implicated in the motor aspects of action production and also the valuation processes that motivate the action. Notably, serotonin was found to condition impulse control and the capacity for behavioral inhibition ([@bib13]; [@bib17]; [@bib62]; [@bib33]) and to promote patience for delayed rewards ([@bib53]; [@bib43]; [@bib65]). Serotonin also impacts the determinants of actions, for instance, how positive and negative outcomes guide learning in humans ([@bib8]; [@bib17]; [@bib27]), monkeys ([@bib10]) and rodents ([@bib4]). Several attempts have been made previously to capture serotonin function in a coherent computational theory. Key ideas are that serotonin (1) regulates the impact of action costs such as punishments ([@bib21]; [@bib44]) or delay ([@bib44]; [@bib14]; [@bib43]) and (2) adjusts the propensity to activate versus inhibit the action ([@bib7]; [@bib14]).

Borrowing from these models, we retain the general working hypothesis that serotonin regulates behavioral activation by modulating the weight of action costs rather than benefits.

We further suggest that the notion of action cost could be more general than initially envisaged. Indeed, in the literature quoted above, actions are mostly implemented as binary responses (e.g., approach vs. avoidance) and their costs or benefits are manipulated through the valence of their outcome (e.g., monetary gain or loss). Such tasks therefore over-simplify the real-life situation, where actions may often require more or less effort, depending on their intensity and duration.

Here, we tested the specific hypothesis that serotonin regulates the weight of effort cost in action production, as opposed to the weight of expected benefit. To assess the impact of changing cerebral serotonin levels and how it unfolds over time, we compared different groups of healthy subjects treated under double blind conditions with escitalopram (an SSRI) or placebo during eight weeks. Participants performed a previously published task ([@bib42]), during which they allocated physical effort over time in order to maximize a monetary payoff that increased with effort duration (see [Figure 1A](#fig1){ref-type="fig"}). The task thus involves trading a physical effort cost against distinct levels of monetary incentives. Although changes in cost and benefit were independently manipulated in the task, they may result in intricate effects at the behavioral level. To disentangle between potential effects of serotonin on cost or benefit estimates, or both, we used a formal model of how decisions are generated by a hidden level of computations in our task, as previously described ([@bib42][@bib41]). Based on this computational analysis of the behavior, we could pinpoint the specific effect of serotonin on cost-related parameters, and track the predicted effects of such a computational change onto the experimental measures.10.7554/eLife.17282.003Figure 1.Task design and behavioral performance.(**A**) The screenshots depict a trial as it was presented to subjects.Subjects were free to allocate their effort as they wished over the 30s corresponding to the trial duration. They were instructed that their monetary payoff would be proportional to both the monetary incentive and the effort duration, i.e. the time spent squeezing a handgrip harder than a target force level, which varied with task difficulty. Subjects were provided with on-line feedback on the payoff accumulated in the trial (score on the top) and on the instantaneous pressure exerted on the grip (fluid level in the thermometer). The force time series of an example trial is shown below the screenshots, revealing 3 effort periods, with rewarded effort (force above target) plotted in black (not gray). Two factors were manipulated across trials: (i) the incentive level, shown as a coin image (1, 2 or 5p) and (ii) the difficulty level, corresponding to the same white bar in the thermometer reached with different target force levels (70%, 80% or 90% of the maximal force). The last screen summarized the payoff cumulated over preceding trials. (**B**) Using a double-blind procedure, healthy subjects were assigned to one of the two treatment groups, corresponding to a daily intake of either placebo or escitalopram (10 mg during the initial phase, 20 mg during the intermediate and late phase) during 9 weeks. Each subject completed the effort allocation task three times at distinct treatment phases (initial, intermediate and late). Numbers of subjects and visits correspond to data sets included in the analysis after compliance and quality checks. (**C**) The three left-most graphs show task performance (as reflected in monetary payoff) sorted by treatment group (black: placebo; gray: escitalopram) and time since treatment onset. Statistical significance was assessed with two-sample, two-sided t-tests. On the right-most plot, payoff was averaged over visits at the subject level. Statistical significance was assessed with ANOVAs including treatments as between-subject factors and test phase (initial, intermediate or late) as a within-subject factor. \*p\<0.05; \*\*p\<0.005. Error bars indicate Student\'s 95% confidence intervals.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.003](10.7554/eLife.17282.003)10.7554/eLife.17282.004Figure 1---source data 1.The MATLAB data file contains the payoff earned by each participant at each visit, in the placebo and escitalopram groups.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.004](10.7554/eLife.17282.004)

Results {#s2}
=======

Escitalopram improves performance in the effort allocation task {#s2-1}
---------------------------------------------------------------

58 subjects were included in the analysis, see [Table 1.](#tbl1){ref-type="table"} We took the cumulated payoff as the primary measure of performance in the task and compared it between groups and visits (see [Figure 1C](#fig1){ref-type="fig"}). We found a significant effect of treatment group: performance was significantly improved in the escitalopram group (F~1,\ 58.4~=9.37, p=0.003) as compared to the placebo group. This difference was stable over time: there was no significant interaction between groups and visits (F~2~, ~91~=0.22, p=0.8). The average payoff per visit was £35.9±1.21 s.e.m. and £30.1±1.44 s.e.m. in the escitalopram and placebo groups respectively.

Escitalopram has a specific computational effect on effort cost {#s2-2}
---------------------------------------------------------------

The better performance observed in the escitalopram group could be underpinned by different mechanisms: alleviation of effort costs or inflation of incentive values, or both. To disentangle between the two mechanisms, we relied on a computational model of effort allocation that was previously proposed ([@bib42]; [@bib41]). This model assumes that a single computational variable, termed cost evidence, accounts for the decision to stop and resume effort exertion. Cost evidence waxes during effort (with slope Se) until reaching an upper bound where effort is stopped, and it wanes during rest (with slope Sr) until reaching a lower bound where effort is resumed. The distance between bounds is the cost-evidence amplitude (denoted A). Effort and rest durations are determined by the ratios of amplitude and slopes (see [Figure 2A](#fig2){ref-type="fig"}) so that performance depends on the value of latent parameters (A, Se, Sr) and its potential modulation by task factors (monetary incentive and effort difficulty). We used a Bayesian Model Selection procedure previously validated ([@bib42][@bib41]) to pinpoint the effect of the task factors onto these latent parameters (see Materials and methods).10.7554/eLife.17282.005Figure 2.Computational results.(**A**) The cost-evidence accumulation model assumes that effort and rest durations are respectively determined by the accumulation (mean slope Se~m~) and dissipation (mean slope Sr~m~) of cost evidence between bounds (mean amplitude A~m~). Possible modulations of these parameters by incentive and difficulty levels were implemented in 20 distinct models. In the best model identified (\#20) by Bayesian selection, increasing effort difficulty shortens effort duration by steepening the accumulation slope (a parametric effect controlled by parameter Se~d~ and illustrated with colors from yellow to red). Increasing the incentive level has two effects: first, it shortens rest duration by speeding up the dissipation (parametric effect of Sr~i,~ illustrated by colors from dark to light blue); second, it lengthens effort duration by pushing back the bounds (parametric effect of A~i,~ illustrated by green scaling). (**B**) Plots show inter-subject means and Student\'s 95% confidence intervals obtained for the fitted values of model parameters (which were averaged over visits at the subject level). To facilitate visual comparison, scales and offsets were adjusted so that mean and error bars are visually equal across plots in the placebo group. Statistical significance corresponds to ANOVAs including treatment group (escitalopram vs. placebo) as a between-subject factor and treatment phase as a within-subject factor (initial, intermediate or late); \*\*p\<0.005. (**C**) Data in the placebo group served as a baseline to simulate effort and rest durations after imposing a 20% increase in computational parameters. In the table, each row corresponds to a simulated change in one single parameter. Colors denote the effect sizes recovered by model fitting for each parameter, as percent of change compared to baseline. Numbers indicate the percentage of \'hit\' (on the diagonal) and \'false alarm\' (off-diagonal) in detecting a significant change in parameter values with a paired t-test thresholded at p\<0.01. (**D**) The graph illustrates why the effect of escitalopram, characterized at the computational level as a reduced accumulation slope of cost-evidence during effort (Se~m~), should translate at the behavioral level into both a longer effort duration and an increased sensitivity of effort duration to incentive level.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.005](10.7554/eLife.17282.005)10.7554/eLife.17282.006Figure 2---source data 1.The MATLAB data file contains the fitted value of parameters A~i~, Se~m~, Se~d~, Sr~m~, Sr~i~ (see Materials and methods, [Equation 2](#equ2){ref-type="disp-formula"}), for each participant at each visit, in the placebo and escitalopram groups.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.006](10.7554/eLife.17282.006)

Replicating our previous studies, the best model showed that incentives impacted the amplitude (A) and dissipation slope (Sr), whereas effort difficulty impacted the accumulation slope (Se), as illustrated in [Figure 2A](#fig2){ref-type="fig"}, right. To capture all the effects, the cost-evidence accumulation model therefore necessitates five free parameters: the mean slope of cost-evidence accumulation (Se~m~) and its steepening for higher difficulty levels (Se~d~); the mean slope of cost-evidence dissipation during rest (Sr~m~) and its steepening for higher incentives (Sr~i~); and the expansion of the cost-evidence amplitude as higher incentives push the bounds back (A~i~). The fact that the same best model was found independently in each treatment group with high confidence levels (exceedance probabilities xp\>98% in each group) indicates that all subjects can be characterized within this common computational framework. We computed for each subject the best-fitting values of the model parameters (A~i~, Se~m~, Se~d~, Sr~m~, Sr~i~). Since the interaction between treatments (placebo vs. escitalopram) and treatment phase was not significant for any parameter (all F~2,\ 91~\<2.03, p\>0.14), we provide fitted values pooled over treatment phases in [Figure 2B](#fig2){ref-type="fig"}.

Only one model parameter was significantly different between the placebo and escitalopram groups: the cost-evidence accumulation slope (Se~m~, F~1,\ 58.0~=9.88, p=0.003). This parameter captures the average value of effort cost across conditions: there was a 31% decrease in the escitalopram group compared to the placebo group (on average with ± s.e.m., placebo: 0.16±0.012, escitalopram: 0.11±0.008); the difference was actually significant at each visit (all p\<0.015; two-sided t-test).

The difference between escitalopram and placebo never reached significance for the other model parameters (all p\>0.08, see [Table 2](#tbl2){ref-type="table"}; on average with ± s.e.m. for placebo vs. escitalopram, A~i~: 0.15±0.028 vs. 0.19±0.022, Se~d~: 0.021±0.004 vs. 0.013±0.002, Sr~m~: 0.37±0.022 vs. 0.42±0.029, Sr~i~: 0.086±0.018 vs. 0.126±0.016). We checked the sensitivity and specificity of our model fitting procedure in detecting a treatment effect through simulations. A 20% change in any given parameter was reliably detected and the difference recovered by model fitting was significant in a 96% of simulations at least for A~i~, Se~m~, Sr~m~ and Sr~i~ and in a 77% of simulations for Se~d~. Importantly, a change in one single parameter was recovered without propagating to other parameters and the false alarm rate was below 5% for all parameters ([Figure 2C](#fig2){ref-type="fig"}).10.7554/eLife.17282.007Table 1.Details on participants N corresponds to the number of subjects per treatment type and phase. A few datasets were not available due technical problems and late withdrawals. Based on criteria specific to the present task (and not to the clinical trial), some subjects were excluded from the analysis (\'excluded\'). We report the age and sex of participants included in the analysis and the exact time of their test since the treatment onset.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.007](10.7554/eLife.17282.007)Treatment typeTreatment phaseN not availableN excludedN after exclusionSex (Male / female)Age (years) ± SD of included subjectsTime since treatment onset (days) ± SD for included subjectsPlaceboInitial052714/1323.4 ± 4.353.0 ± 0.68PlaceboIntermediate062614/1223.2 ± 4.3313.8 ± 1.13PlaceboLate042815/1323.4 ± 4.2754.7 ± 4.98EscitalopramInitial182311/1224.5 ± 4.713.1 ± 0.63EscitalopramIntermediate162512/1324.5 ± 4.5114.0 ± 0.87EscitalopramLate262410/1424.6 ± 4.6155.3 ± 4.6910.7554/eLife.17282.008Table 2.Treatment effect on computational parameters and behavioral measures. All numbers are p-values obtained from ANOVAs. p-values lower than 0.05/5=0.01 (computational parameters) and 0.05/6=0.008 (behavioral measures) appears in bold to show significant effects that survive correction for multiple comparisons.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.008](10.7554/eLife.17282.008)VariableTreatmentVisitInteractionA~i~0.3880.1970.406Se~m~**0.003**0.0390.260Se~d~0.07970.5430.137Sr~m~0.1860.7780.612Sr~i~0.1300.1960.557Effort duration -- mean**0.002**0.1990.875Effort duration -- sensitivity to incentive0.0230.1870.115Effort duration -- sensitivity to difficulty0.2470.8130.318Rest duration -- mean0.2130.4820.531Rest duration -- sensitivity to incentive0.1620.9370.807Rest duration -- sensitivity to difficulty0.1150.4230.681

To further test the specificity of SSRI effect on cost-evidence accumulation, we performed another Bayesian model selection that contrasted the two groups of subjects. Parameters of the cost-evidence accumulation model were fitted on the placebo group data to serve as a reference. In the escitalopram group, they were fixed to these reference values and only one or two modulations were permitted to capture the treatment effects. Models including a modulation of Se~m~ outperformed the others (log Bayes Factor, all Δ\>147.9), see [Table 3](#tbl3){ref-type="table"}. A version with modulations of both Se~m~ and Se~d~ was slightly more likely than a version with only a modulation of Se~m~ (Δ=3) and much more likely than any other combination (Δ\>5.9).10.7554/eLife.17282.009Table 3.Model comparison assessing the specificity of treatment effect.Data in the escitalopram group were fitted with the cost-evidence accumulation model. The parameters were fixed to the values fitted onto the placebo group, excepted when a modulation was permitted. The first row contains models that permit the modulation of one single parameter, whereas the remaining rows correspond to models that permit a combination of two modulations. Each cell gives log Bayes Factor (i.e. log model evidence) relative to the null model. Higher values denote better models.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.009](10.7554/eLife.17282.009)Se~m~Se~d~Sr~m~Sr~i~A~i~Only one modulation173.619.9−4.2−3.83.7Also includes Se~m~176.6169.6169.7170.7Also includes Se~d~15.716.121.7Also includes Sr~m~−7.3−1.1Also includes Sr~i~1.2

Thus, the specific effect of SSRI on cost-related parameters supports our hypothesis that serotonin is involved in the estimation of action cost, rather than benefits.

Computational effects of escitalopram translate into behavioral effects {#s2-3}
-----------------------------------------------------------------------

Reducing the effort cost (Se~m~) only should have two effects at the behavioral level (see [Figure 2D](#fig2){ref-type="fig"}). The first is straightforward: the duration of effort epochs should be longer. The second is less trivial: the sensitivity of effort duration to incentive level should be increased. This is because in our model, incentive level modulates the amplitude between bounds (as captured by parameter A~i~). Thus, the effect of incentive level on effort duration is proportional to the accumulation slope Se~m~: if the accumulation is slower, then a given displacement of the upper bound will have a larger effect on effort duration.

Fulfilling these predictions, we found both a longer effort duration per se (F~1,\ 58.1~=10.72, p=0.002, on average placebo: 7.63s±0.56, escitalopram: 10.2s±0.55, with s.e.m.) and a higher sensitivity of effort duration to incentive level (F~1,\ 58.5~=5.46, p=0.023, on average with ± s.e.m., placebo: 1.11±0.22, escitalopram: 1.95±0.26) in the escitalopram group compared to placebo (see [Figure 3A](#fig3){ref-type="fig"}). The difference between the two treatment groups never reached significance for the other behavioral variables (all p\>0.11, on average with ± s.e.m., for placebo vs. escitalopram, effort sensitivity to difficulty: −0.84±0.13 vs. −1.06±0.14, rest duration: 3.17s±0.19 vs 2.85s±0.19, rest sensitivity to incentives: −0.19±0.04 vs. −0.30±0.05, rest sensitivity to difficulty: 0.077±0.018 vs. 0.025±0.03).10.7554/eLife.17282.010Figure 3.Behavioral results.(**A**) Plots show inter-subject means and Student\'s 95% confidence intervals obtained from linear regression.Regression coefficients were averaged over visits at the subject level. To facilitate visual comparison, scales and offsets were adjusted so that mean and s.e.m. are visually equal across plots in the placebo group. Statistical significance corresponds to ANOVAs including treatment group (escitalopram vs. placebo) as a between-subject factor and treatment phase as a within-subject factor (initial, intermediate or late); \*p\<0.05, \*\*p\<0.005. (**B**) As predicted by the cost-evidence accumulation model, effort duration and its sensitivity to incentive level are correlated across subjects (one dot corresponds to one subject; values were averaged across visits for each subject). The line shows the linear regression fit obtained when pooling the two treatment groups (ρ~56~=0.55, p\<10^--5^).**DOI:** [http://dx.doi.org/10.7554/eLife.17282.010](10.7554/eLife.17282.010)10.7554/eLife.17282.011Figure 3---source data 1.The MATLAB data file contains a description of the behavior obtained by linear regressions for each participant at each visit, in the placebo and escitalopram groups.The regression weights correspond to the mean effort duration and mean rest duration, and their modulation by incentive levels and difficulty levels.**DOI:** [http://dx.doi.org/10.7554/eLife.17282.011](10.7554/eLife.17282.011)

Crucially, because they arise from a common cause, the model also predicts that the two effects should be correlated: the more Se~m~ is reduced, the more effort duration and its sensitivity to incentive level should be increased. The Pearson correlation over subjects was indeed significantly positive in both groups (placebo: ρ~27~=0.43, p=0.02; escitalopram: ρ~27~=0.54, p=0.002, see [Figure 3B](#fig3){ref-type="fig"}).

Discussion {#s3}
==========

Our behavioral results in healthy volunteers show that the SSRI escitalopram improves global performance and hence payoff in a task that involves trading effort cost against monetary benefit. Taking advantage of the independent manipulation of cost and benefit, our computational analysis characterized the effect of escitalopram as a specific diminution of effort cost.

Together with previous findings, our results support the hypothesis that cost may be a general functional domain for serotonin ([@bib7]; [@bib22]). For instance, interventions targeting serotonergic transmission during probabilistic and reversal learning paradigms in rodents, monkeys and humans suggested that serotonin impacts sensitivity to negative rather than positive feedback ([@bib10]; [@bib8]; [@bib17]; [@bib4]; [@bib12]). The reduction of serotonergic transmission in humans following acute tryptophan depletion (for a review, see [@bib27]) reduced information sampling in a decision-making task, but crucially, only when sampling had a financial cost ([@bib18]). Serotonin may also impact moral costs, such as unfairness in social decision-making ([@bib19]). Furthermore, serotonin may control the cost of delay in reward delivery in rodents, such that a higher firing rate of serotonergic neurons correlates with an increased ability to wait for bigger rewards ([@bib43]), without affecting the sensitivity to the reward itself ([@bib30]). Conversely, low serotonin levels, e.g. after acute tryptophan depletion, were suggested to exacerbate sensitivity to the cost of waiting, which could result in impulse control disorders ([@bib17]; [@bib14]; [@bib22]). Thus, it is tempting to build a parsimonious computational theory on the idea that serotonin is involved in processing all kinds of action costs. This is compatible with the notion that different types of costs are processed by distinct neural circuits, since neuromodulators such as serotonin can affect many brain regions. However, such a generalization would necessitate assessing the putative role of each mono-amine and their interactions with different types of costs within the same study. Previous attempts in rodents have observed effects that are inconsistent with the present results: in cost/benefit trade-off tasks, serotonin blockers impacted choices only when costs were delays, and not physical efforts ([@bib23]), whereas dopamine blockers affected both types of costs. Such discrepancies may call for caution when translating the results of pharmacological studies in rodents into medication effects in humans.

A general role for serotonin in cost processing also seems compatible with the effects on apathy and impulsivity reported in healthy and pathological conditions ([@bib13]; [@bib48]; [@bib53]; [@bib17]; [@bib64]; [@bib62]; [@bib33]; [@bib43]; [@bib65]). Indeed, according to our interpretation, SSRIs might reduce the perceived cost of performing actions, which would promote behavioral activation, hence the alleviation of apathy. As SSRIs might also reduce the perceived cost of delaying action, they would improve response control and reduce impulsivity ([@bib13]; [@bib14]; [@bib17]; [@bib22]; [@bib3]; [@bib43]; [@bib30]).

However, it is important to note that the SSRI effects obtained here relate to effort cost and not to time discounting. Although time is central in our task, it departs from delay and waiting paradigms in several respects. First, the overall task duration was fixed and its pace was independent from how subjects allocated their effort within trials. Second, the reward was gained instantaneously, concomitantly to effort production, without delay. Therefore, the SSRI effect on effort duration (how long subjects sustain an effort) cannot be explained by a change in temporal discounting (how long subjects wait for a reward).

The direction of the effect obtained in the present study suggests that higher serotonin level alleviates the effort cost. This interpretation is based on the assumption that the primary effect of SSRI is to increase serotonin level in the synaptic cleft ([@bib45]; [@bib56]). However, the net effect of SSRI might not be so straightforward to interpret at the molecular level for several reasons. First, a high tonic concentration could have the paradoxical effect of reducing the sensitivity to phasic serotonergic signals ([@bib27]). Second, the ubiquitous negative feedback regulation by auto-receptors can initially revert the response expected from high extracellular levels of serotonin ([@bib56]; [@bib29]) and also produce non-linear dose-response functions for cognitive performance ([@bib4]). Third, much evidence suggests that different serotonin projections to different forebrain systems mediate varying acute and chronic adaptive responses to aversive events ([@bib34]; [@bib27]). The effect of serotonin also depends on the location in the brain and on the type of receptors, for instance, 5-HT1A and 5-HT2A receptors respectively inhibit and excite motoneurons ([@bib38]). Thus, the superficial interpretation that serotonin helps overcoming effort costs will need to be refined by addressing the complexity of SSRI effects at the molecular level. We nevertheless note that the superficial interpretation is consistent with demonstrations that serotonin also helps overcoming other costs such as delay in humans ([@bib53]).

Refinement is also needed at the computational level. Our model does not specify how exactly serotonin could attenuate the impact of effort cost on action production. An indirect effect through an increase in muscular capacity can be excluded since there was no difference in maximal force between the placebo and SSRI groups at any visit. The computational analysis simply suggests that a slower accumulation of effort cost (lower Se~m~) under SSRI prolonged effort duration. It does not distinguish between down-regulation of the cost signal itself, or down-regulation of the weight this cost has in the decision to produce an effort. The former (perceptual) view would be in line with an analgesic effect of escitalopram, which is consistent with the findings that nociception and/or somatosensory perception are both modulated by serotonin at central levels ([@bib38]), that serotonin is targeted by common drugs modulating pain like acetaminophen ([@bib55]) and that serotonin modulates the inhibitory feedback loop that allows muscular fatigue to down-regulate the motor command ([@bib32]; [@bib15]). The latter (decisional) view would be more generalizable to the capacity of overcoming other types of costs.

As the serotonin and dopamine systems strongly interact ([@bib25]; [@bib14]; [@bib52]; [@bib29]), the SSRI effect observed here might also be at least in part mediated by dopamine. Indeed, the beneficial effect of SSRI shown here is reminiscent of previous reports about dopaminergic manipulations in mesolimbic structures, which affected the propensity to choose high reward -- high effort over low reward -- low effort options in rodents ([@bib16]; [@bib50]). However, if SSRIs antagonize dopamine release ([@bib25]; [@bib14]), escitalopram should have reduced effort production in our task (but see [@bib52]). Moreover, the fact that escitalopram did not modulate incentive effects on parameters such as the amplitude or dissipation slope argues against a participation of dopamine. Indeed dopaminergic manipulations in humans have been repeatedly shown to affect reward processing, not only in learning contexts ([@bib31]; [@bib49]; [@bib47]) but also in reward/effort trade-off paradigms ([@bib63]; [@bib60]; [@bib40]). It might be that serotonin and dopamine have complementary roles in promoting action production (and alleviating apathy): the former by reducing effort cost and the latter by enhancing the incentive value of potential rewards.

Previous studies suggest that we should distinguish between acute and chronic effects of SSRIs ([@bib29]). We did not find an interaction with time in our results but only a main effect of treatment group. Both parametric and non-parametric statistics showed that such a group difference is very unlikely to arise from chance in sampling the population (under the null hypothesis). General psychological assessment at baseline was also similar in the two groups. However, we acknowledge that our shortest time since treatment onset (3 days) may already depart from the acute regime, that ceiling effects in the SSRI group could in principle mask an interaction with time, and that our study may lack the statistical power to reveal such an effect. This absence of an interaction contrasts with the apparently delayed clinical effect of SSRIs in depressed patients, which usually take weeks to improve mood ([@bib56]). However, at the molecular level, serotonin release is boosted by SSRIs from treatment onset ([@bib39]) and SSRI effects on emotional processing also occur with little or no delay in healthy subjects ([@bib35]). In pathological conditions, time may be needed to adjust to the new, less negative perception of costs, as well as the reduced emotional bias, and convert these implicit changes into a conscious subjective improvement that can be reported to the practitioner ([@bib36]; [@bib14]). This idea has been formalized in a recent study showing how positive and negative outcomes can shape mood on the long run ([@bib26]). Further studies in depressed patients are needed to assess whether an early detection of effort cost attenuation could be used to predict long-term treatment effects on clinical symptoms.

Finally, our results also indicate that non-trivial behavioral effects can be accounted for by a change in a single computational parameter (Se~m~): a specific modulation of cost can result in both longer efforts and an increased sensitivity of effort duration to potential benefits in our results. Intuitively, this effect on reward sensitivity corresponds to the idea that when perceived costs are too high, a change in reward prospect will have little effect. Thus, our analysis shows that the behavioral consequences of cost and benefit estimates are intricate but computationally tractable. Our paradigm and model could provide experimental and conceptual tools to refine the description of motivational disorders. Distinct dysfunctions, such as amplification of effort cost vs. flattening of reward prospects, might call for different treatments: if drugs modulating serotonin only affect cost estimates, then other drugs (possibly dopaminergic) should aim to impact the valuation of potential benefits.

Materials and methods {#s4}
=====================

Participants {#s4-1}
------------

Healthy volunteers (18--45 years old) were recruited to the study by public advertisement after approval by the Ethics Committee of Berkshire, UK (protocol CL1-20098-81, on 28th Sept. 2011) and registration as a clinical trial, ISRCTN75872983. Participants gave their written informed consent prior to participation. Normal health was checked by clinical and psychiatric examinations including laboratory tests. Exclusions and withdrawals from the study were adjusted to include 64 participants (2 treatment groups of 32 participants, 16 men per group), tested at 3 separate visits, resulting in 192 completions of the task. Given that the clinical trial was exploratory and also included tests from other research groups, the sample size was not selected specifically for our study; however it appeared reasonable given typical studies in the field. Indeed, published between-subject comparisons of placebo and anti-depressant treatments were made on a lower sample size per group (e.g. N=14 in [@bib37], N=20 in [@bib8] and N=30 in [@bib33]), and a single visit per subject (while we have three). Due to technical problems or late withdrawals, 4 task completions were not fully acquired and therefore unusable. The remaining data were checked for quality by F.M. prior to unblinding: 11 were excluded due to mis-calibration of task difficulty; 9 due to hardware default or signal quality; 15 for non-compliance with task instructions. Subjects were asked to produce an effort in every trial. As there were eight trials per condition in the task, a given visit was excluded for non-compliance when the total number of effort (or rest) was lower than three in at least one condition. As a result, the number of participants per visit varied between 23 and 28 in each treatment group, for a total of 153 task completions. Note that a given participant may produce an interpretable dataset at a given visit and not at another. The total number of participants with at least one interpretable dataset across the three visits happened to be 29 in each treatment group. The finally included data set is summarized in [Table 1](#tbl1){ref-type="table"}.

Sex ratio (14/29 vs. 16/29, Z test for proportion: z= 0.53, p=0.6), ratio of excluded data sets (15/96 vs. 20/92, z=1.08, p=0.28) and age (mean with ± s.e.m., 23.2 ± 0.8 vs. 24.2 ± 0.8, p=0.38) were similar in the two groups. We also used psychological tests to assess differences between groups of subjects at baseline, before treatment. T-test comparison showed no significant difference in Mood Visual Analog Scales for the items \'happy\' (p=0.75), \'sad\' (p=0.96), \'hostile\' (p=0.48), \'alert\' (p=0.73), \'anxious\' (p=0.51), \'calm\' (p=0.14), nor in the Hospital Anxiety Depression score for anxiety (p=0.68) and depression (p=0.35). The difference in State-Trait Anxiety Inventory score was at p=0.04 at baseline but p=0.45 and p=0.83 after 7 and 55 days of treatment respectively. Therefore, psychological variables were not significantly different at baseline when correcting for multiple comparisons (at p=0.05/9) and the one passing the uncorrected threshold p=0.05 was not significantly different during the testing phase.

Drug and testing schedule {#s4-2}
-------------------------

Two centers participated in the study (Oxford and Manchester, UK). Data were collected between January 2012 and July 2013. Participants were randomly assigned to one of the two parallel treatment groups following a double-blind procedure: placebo or escitalopram (10 mg during week \#1 and \#9; 20 mg from week \#2 to \#8). The randomisation list was constructed in blind, by the Institut de Recherches Internationales Servier, with stratification by gender and center (Oxford, Manchester). Treatments were conditioned by Les Laboratoires Servier Industrie so as to be visually indistinguishable and shipped in numbered containers to the investigators. The randomisation list was not made available to the investigators until the final data set had been checked for quality and locked by transfer to a Contract Research Organization (Biotrial). Participants took a daily oral capsule around 8 P.M. for 9 weeks and performed the Effort Allocation Task three times at distinct latencies ([Figure 1B](#fig1){ref-type="fig"}): initial (2--4 days after treatment onset), intermediate (12--17 days) and late (52--60 days for all subjects but 3, who were tested between the 33rd and 44th days before withdrawing from the study). The task was not performed on week \#9. The clinical trial included other tests, not presented here, to assess emotional processing, sexual acceptability and learning abilities. Safety evaluations (adverse events collection, blood pressure/heart rate and laboratory test) were performed along with the study.

Experimental set-up {#s4-3}
-------------------

The Effort Allocation Task is schematized in [Figure 1A](#fig1){ref-type="fig"} and detailed in a previous publication ([@bib42]). The only change was the adoption of the local currency (British pounds). On each trial, participants had 30 s that could be spent either resting or squeezing a handgrip. They were instructed that the payoff would be proportional to both the monetary incentive and the time spent above a force target corresponding to effort difficulty. The task lasted approximately one hour and was split into 8 blocks. The factor levels (monetary incentives: 1, 2 or 5p and effort difficulty: 70, 80, 90% of the maximal force) were manipulated independently and crossed, resulting in 9 conditions, each corresponding to a trial, presented in a randomized order in each block. Left and right hands were used alternatively over blocks. Participants were encouraged to maximize their payoff at each trial, and told that the cumulated payoff would be added to their financial compensation for participating in the study. Unbeknown to them, this payoff was rounded up to a fixed amount after the last visit such that all participants eventually received the same total. The task difficulty was adjusted to the subject\'s maximal force, which was measured at each visit before the test. The procedure for measuring the maximal force (sustained handgrip squeezing) is detailed in ([@bib42]) and follows published guidelines ([@bib32]). The maximal force was not affected by treatments (F~3,\ 113.7~=0.93, p=0.42), visits (F~2,\ 180~=1.34, p=0.26) or by the interaction of these two factors (F~6,\ 180~=0.27, p=0.95).

Behavioral analysis {#s4-4}
-------------------

The cumulated effort duration determined the payoff obtained at each trial. Yet there are many ways of chunking this cumulated duration depending on the duration of each effort and rest epochs. Effort and rest epochs were determined based on the force time series ([Figure 1A](#fig1){ref-type="fig"} provides an example) using an off-line algorithm ([@bib41]). The offline detection algorithm was based on both the force signal normalized by the calibration maximal force, and its temporal derivative. Samples with positive derivative, exceeding one standard deviation of the derivative time series, and force level higher than 0.5 (half the maximum) were tentatively marked as effort onsets. Effort offsets were defined similarly for negative derivative values and force levels below 0.5. When multiple offsets were detected between two onsets, all but the last one were discarded. If multiple onsets were detected before an offset, the one with minimum force was kept. An offset was marked at the trial end if the effort was still sustained at that moment. Elapsed time between effort onsets and offsets determined effort and rest durations. The first rest duration was the elapsed time between trial onset and the first effort onset.

We performed a model-free analysis of the behavior, for each subject and visit, with multiple linear regressions done separately for effort and rest durations. The linear models included the factors of interest (incentive and difficulty) and temporal factors (block number; trial number within a block, effort or rest epoch number within a trial). Regressors (excepted the constant) were z-scored so that regression coefficients (beta estimates) correspond to standardized effect sizes. These beta values were then compared between treatments using ANOVA (see statistical analysis below).

Computational analysis {#s4-5}
----------------------

### The cost-evidence accumulation framework {#s4-5-1}

To account for the decision to stop and resume effort exertion in our task, we previously developed a computational model that was supported by both behavioral and neuroimaging data ([@bib42]; [@bib41]). The central assumption of our model is that the allocation of effort over time is underpinned by the variation of a single computational variable. This decision variable waxes during effort until reaching an upper bound, which triggers effort cessation, and wanes during rest until reaching a lower bound, which triggers effort resumption. The model thus has three latent parameters: the accumulation ($S_{e}$) and dissipation ($S_{r}$) slopes of cost evidence and the amplitude of these variations (*A*; the distance between bounds). The ratios of amplitude and slopes determine the effort and rest durations (see [Figure 2A](#fig2){ref-type="fig"}).

The computational analysis, detailed below, aimed at (1) identifying how the model latent parameters are modulated by the task factors (incentive and difficulty levels), (2) testing whether these modulations differ between treatment groups and (3) assessing the specificity and sensitivity of our fitting procedure in detecting potential differences between treatment groups.

### Model fit and selection {#s4-5-2}

In this section, we provide details about model fit and model selection, although we followed the exact same methods as reported in our previous publication ([@bib42]).

In principle, each model latent parameter (accumulation slope $S_{e}$, dissipation slope $S_{r}$ and amplitude of variations $A$) could be modulated by each task factor, which we formalized as linear effects:$$\begin{array}{l}
{Te = \frac{A}{Se};Tr = \frac{A}{Sr};} \\
\begin{cases}
A & {= A_{m} + A_{i}I + A_{d}D} \\
{Se} & {= Se_{m} + Se_{i}I + Se_{d}D} \\
{Sr} & {= Sr_{m} + Sr_{i}I + Sr_{d}D} \\
\end{cases} \\
\end{array}$$

where $T_{e}$ and $T_{r}$ are the mean durations of effort and rest epochs (fitted across experimental conditions); *I* and *D* are the z-scored incentive and difficulty levels; $A_{i}$, $A_{d}$, $Se_{i}$, $Se_{d}$, $Sr_{i}$ and $Sr_{d}$ capture potential modulations by task factors. The goal of model selection was to identify whether allowing fewer modulations, e.g. only $A_{i}$, $Se_{d}$ and $Sr_{i}$, could still provide a reasonable goodness-of-fit. In total, there are 2^6^=64 possible combinations of the six modulations by task factors. However, we noted in ([@bib42]) that only 20 combinations can a priori reproduce the behavioral effects observed in the effort allocation task (and potentially other effects): increased $T_{e}$ with incentive, decreased $T_{r}$ with incentive, and decreased $T_{e}$ with difficulty. These 20 models correspond to four possible combinations of the incentive effect: $\left\{ A_{i},Se_{i},Sr_{i} \right\}$ or $\left\{ A_{i},Se_{i} \right\}$ or $\left\{ A_{i},Sr_{i} \right\}$ or $\left\{ Se_{i},Sr_{i} \right\}$ crossed with five possible combinations of the difficulty effect: $\left\{ A_{d},Se_{d},Sr_{d} \right\}$ or $\left\{ A_{d},Se_{d} \right\}$ or $\left\{ A_{d},Sr_{d} \right\}$ or $\left\{ Se_{d},Sr_{d} \right\}$ or $\left\{ Se_{d} \right\}$. Besides these modulation terms, all models also included the mean accumulation and dissipation slopes, $Sr_{m}$ and $Se_{m}$, as free parameters. Since effort and rest durations are determined by the ratios of amplitude and slopes in [Equation 1](#equ1){ref-type="disp-formula"}, the mean amplitude $A_{m}$ was not considered as a free parameter; it was fixed to one, so that each subject could be characterized by a unique set of best-fitting parameter values instead of an infinity of proportional solutions.

We used Bayesian model selection to identify a solution with the best tradeoff between goodness-of-fit and simplicity (number of modulation terms in the model). The 20 models were fitted for each subject and visit separately using a variational Bayesian procedure described in ([@bib20]). We used non-informative priors for the fitted parameter values. This variational procedure provides, for each visit and model, the posterior mean values of the latent parameters and the model evidence. The latter is a key summary statistic on the basis of which the best model is identified ([@bib57]; [@bib20]). In order to obtain a single summary statistic per subject, we took the joint (i.e., product of) model evidence over visits. The algorithm used for group-level, random-effect Bayesian Model Selection is described in ([@bib57]) and implemented in the Matlab toolbox SPM8 (Wellcome Department of Imaging Neuroscience, London, UK; function spm_BMS.m).

### Best computational model identified {#s4-5-3}

In both treatment groups, Bayesian model selection (see [Figure 2A](#fig2){ref-type="fig"}) identified the following model as providing the best trade-off between simplicity and goodness-of-fit of the data:$$\begin{array}{l}
{Te = \frac{A}{Se};Tr = \frac{A}{Sr};} \\
\begin{cases}
A & {= A_{m} + A_{i}I} \\
{Se} & {= Se_{m} + Se_{d}D} \\
{Sr} & {= Sr_{m} + Sr_{i}I} \\
\end{cases} \\
\end{array}$$

This is the same best model as in our previous publication ([@bib42]), although it is fitted on different subjects. Fitted parameter values were on average positive such that higher incentives expanded the bounds of cost-evidence variations and quickened its dissipation during rest and higher difficulty levels increased the accumulation rate of cost-evidence during effort (see [Figure 2B](#fig2){ref-type="fig"}).

This computational model can be interpreted as follows, for a more complete discussion see ([@bib42][@bib41]). The accumulation of cost evidence may reflect the build-up of physiological fatigue: the instantaneous effort cost increases as it becomes gradually more difficult to sustain a given force level. As expected from a physiological perspective, fatigue builds up more quickly when higher force levels are exerted, which is captured by $Se_{d}$. An upper bound on the accumulation process ensures that instantaneous cost remains within a certain range that is adjusted to the reward rate. Indeed, the bound is pushed back for higher incentives (which is captured by $A_{i}$), as if an extra cost is allowed when a higher benefit makes it worthy. The bounded accumulation mechanism therefore seems to control the balance between cost and benefit, which could be implemented as an opponency between brain systems ([@bib21]; [@bib2]).

The dissipation of cost evidence may reflect that it takes time to recover full exercising capacity after a strenuous effort. Interestingly, effort was not resumed immediately after cessation, but only after a substantial decrease in cost evidence. Waiting until a lower bound is reached may ensure that effort is not systematically produced at maximal instantaneous cost. Rest may therefore contribute to optimizing the cost/benefit balance on the long run. Importantly, an exceedingly long rest would also be suboptimal since it would reduce the payoff. Indeed, only efforts are rewarded in the task: there is therefore an opportunity cost to rest ([@bib44]). This opportunity cost seems to be taken into account since the cost-evidence dissipation is speeded up for higher incentives (which is captured by $Se_{i}$), so that effort can be resumed more quickly.

### Specificity and sensitivity of the fitting procedure {#s4-5-4}

The fitted parameter values were then compared between treatment groups (see below). We used simulations to assess whether our fitting procedure can detect specific changes in the model parameters between groups. For each subject in the placebo group, we fitted the model and took the mean value over visits of a given parameter (henceforth the \'target\'). To simulate a potential effect of the SSRI treatment on this target parameter, we increased this value by a 20%. Then we computed mean effort and rest durations in each experimental condition using [Equation 2](#equ2){ref-type="disp-formula"} and we corrupted these means with noise (we added the residuals of fitted data taken from another random subject in the placebo group). Last, we fitted again the model by adjusting a second set of parameters onto these simulated mean effort and rest durations. To assess statistical significance, we repeated this procedure 100 times for each subject and each target parameter. We compared the initial parameter values (fitted on actual data) and the new ones (fitted on simulated data) for each simulation with paired t-test across subjects and the threshold p\<0.05/5 to correct for the 5 parameters tested. For \'target\' parameters, a significant difference indicates that the fitting procedure correctly recovers the simulated increase (a \'hit\'); for \'non-target\' parameters, a significant difference indicates a lack of specificity (a \'false alarm\'). We report the simulated changes identified by the fitting procedure in [Figure 2C](#fig2){ref-type="fig"}, as the median parameter change (across subjects), averaged over simulations.

### Specificity of the treatment effect {#s4-5-5}

We also used Bayesian model comparison to test the specificity of treatment effect on computational parameters. We performed this comparison at the group level since our design is between-subject and different subjects may have different parameter values irrespective of the treatment type. To this end, we concatenated across subjects the mean effort and rest durations per condition, separately for each group. The parameters of the accumulation model ([Equation 2](#equ2){ref-type="disp-formula"}) were fitted onto the placebo group data. These fitted values served as reference: A~i~^REF^, Se~m~^REF^, Se~d~^REF^, Sr~m~^REF^, Sr~i~^REF^. We then modeled the potential treatment effect in the escitalopram group as a modulation of the reference parameters: A~i~ = A~i~^REF^\*(1+δ~Ai~), Se~m~= Se~m~^REF^\*(1+δ~Sem~), and so on for Se~d~, Sr~m~ or Sr~i~. For each parameter, the sign and value of δ captures the direction and strength of the treatment effect with respect to the placebo group. We designed single-modulation variants of the accumulation model ([Equation 2](#equ2){ref-type="disp-formula"}) by forcing δ to zero for all but one parameter, for which δ remained free. In other words, a modulation of only one single parameter was permitted. We also designed double-modulation models in which two modulations are permitted and modeled with distinct δs. All models were fitted with the variational Bayesian procedure by ([@bib20]). Values of log model evidence are reported in [Table 3](#tbl3){ref-type="table"} for model comparison.

Statistical analysis {#s4-6}
--------------------

We characterized the effect of treatments on (1) the monetary payoff, (2) the fitted parameters of the best computational model ([Equation 2](#equ2){ref-type="disp-formula"}), (3) the regression coefficients of the model-free analysis. We provide source data files for each of these three sets of variables. We used a repeated-measure ANOVA with subjects as a random factor, treatment group as a between-subject factor and time since treatment onset (initial, intermediate, late) as a within-subject factor. Interaction between the within-subject factors was included in all ANOVAs. We followed up the ANOVA results with two-sample two-sided t-tests at a given time since treatment onset. Significance levels corrected for comparing multiple variables are included in [Table 2](#tbl2){ref-type="table"}.

Given our large sample size (N=58 included subjects), these classical parametric statistics reliably quantify the likelihood that the observed differences between treatment groups reported in our study may be due to chance in sampling the population. Indeed, we confirmed these significance levels with non-parametric permutation tests, using 10,000 permutations of treatment labels between subjects to estimate the probability that an equal or more extreme statistic (F or T depending on the test) could occur by chance.
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"A specific role for serotonin in overcoming effort cost\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by Joshua Gold as the Reviewing Editor and Sabine Kastner as the Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Read Montague (Reviewer \#1); Roshan Cools (Reviewer \#3).

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

This study used a physical effort/incentive-based task with two groups of subjects -- one taking escitalopram, the other placebo -- to test whether SSRIs, and putatively serotonin, have an effect on the amount of effort human subjects will expend to get a reward. Several of the authors had previously developed a rise-to-bound computational model to account for behavior on this task in terms of a \"cost evidence\" variable that rises during effort and falls during rest. Here they used the model to show that overall better performance of the SSRI group (more reward) is associated with reduced effort costs and not the weight in monetary incentives. Thus, 5HT\'s role in action costs might be more general than hitherto thought, extending from the regulation of punishment and delay to that of effort costs.

The reviewers all agreed that this is an excellent paper: interesting, well done, and well written. The role of serotonin in behavioral control and decision-making is complex, and this paper makes a solid contribution to shrinking some of this complexity by sharpening our understanding of it in relation to effort. The ubiquity of SSRI use -- in depression, Parkinson\'s Disease, and other disorders -- and the lack of model-based understanding of what these drugs do in terms of information processing makes the contribution important. It is also commendable from a clinical perspective that chronic rather than just acute effects of the drug were assessed.

Essential revisions:

1\) Several reviewers thought that the model needed to be explained better, and the modeling results analyzed more thoroughly.

A\) Specifically, the text only briefly refers to specific parameters (\"amplitude, accumulation and dissipation slopes of the cost-evidence decision variable\") that a reader without thorough familiarity of the earlier papers will have a hard time following. It would be useful to describe the model in the text. Likewise, the model parameters are listed (\"A~i~, Se~m~, etc.) without being explained. For more context, it might also be useful to relate their model more directly to the RL model in Daw et al. 2002 referenced in the paper, and also the model in Balasubramani et al. 2015, Frontiers of Computational Neuroscience.

B\) More substantively, there were questions about the specificity of the effect from the modeling analyses. It is stated that interactions between treatments and pairs of computational variables (Se~m~ versus each other parameter) were always significant. The implication of this result depends on the sign of the parameters. The cumulative payoff effect might represent, for example, enhanced amplitude modulation (A~i~) and/or reduced cost-evidence accumulation (Se~m~). How were computational parameters coded when entered into the ANOVA? To assess specificity, one might want to reverse the coding for A and Sr. More generally, to what extent were the parameters independent of each other in the model? Also, might it be possible to define a different model space that would allow the use of Bayesian stats, and model comparison to estimate the drug effects on the various parameters? The distinct advantage of such an approach would be that it allows the capturing of drug effects despite the presence of individual differences of no interest.

C\) Is any background \'reference\' neuropsychological data available to confirm that there were no group differences of no interest? If so, please report.

2\) There were questions about the interpretation of the effects in terms of the role of time in task performance. The main effects coming out of the modeling analysis appear to be related to effort duration. But longer effort durations are also longer overall durations, which brings up the literature on 5-HT and delay costs (some of the delay discounting papers with 5-HT manipulations are actually cited in the manuscript). The authors appear to favor the view that different types of costs can be reduced to one process that is related overall to multiple types of costs. There is evidence both for and against this, and the authors are of course free to interpret their results in this way. In fact, this discussion contributes to the field in an interesting way. However, how much of the effect they are seeing is related to time per se? The authors should discuss this.

3\) The Introduction might benefit from mentioning the implication of 5HT not just in apathy, but also in the other end of the motivation continuum, that is impulsivity. And in the Discussion, how do the findings relate to observations that 5HT is key for impulse control? More generally, the paper might come full circle, by linking, in the Discussion section, the obtained results to these various clinical hypotheses (involvement in apathy, impulsivity).

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"A specific role for serotonin in overcoming effort cost\" for further consideration at *eLife*. Your revised article has been favorably evaluated by Sabine Kastner (Senior editor), a Reviewing editor (Joshua Gold), and one new reviewer, who offered input from a statistical perspective. The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined by the reviewer:

*Reviewer \#4:*

I have reviewed this paper from a statistical perspective as this is a registered trial.

This manuscript presents the analysis of a single randomised placebo controlled and double blinded study. It is not a trial of an intervention but rather a controlled study to understand the mechanism of action that the specific drug takes. The trial has been registered with a target sample size of 128 and it has a single hypothesis statement that aims to \'assess the effects of\' agolmelatine and escitalopram on emotional binding, emotional processing and motivation\'. Each participant is measured over several tasks during the treatment period of 9 weeks.

I realise that it is not in the *eLife* style to report numerical estimates in the Abstract but as this report analyses a single controlled experiment I think they should put the strength of the evidence in the Abstract to back up their statement that \'they show that serotonin also regulates other types of action costs such as effort\'. As there is no replication they should report this in a more guarded manner.

The authors have completed the Consort statement but they need to provide more complete information within the manuscript so they can say yes to more of the checklist.

The trial registration lists a compound aim/hypothesis and also lists three primary outcomes listed which I think have all been used in this analysis but the main question for the manuscript is \'does serotonin regulate the weight of effort cost as opposed to the weight of expected benefit?\'

I would like to see a clearer link between the main research question and the forms of analysis. A sample size of 58 is not that large even with repeated measurement. Was there really any power to test for interactions? The Consort checklist says \'no\' to sample size but surely the size was justified originally? I feel a bit concerned that sometimes Bonferonni correction is used to conclude there were no differences when this just reduces power.

10.7554/eLife.17282.015

Author response

*Essential revisions:*

*1) Several reviewers thought that the model needed to be explained better, and the modeling results analyzed more thoroughly.*

*A) Specifically, the text only briefly refers to specific parameters (\"amplitude, accumulation and dissipation slopes of the cost-evidence decision variable\") that a reader without thorough familiarity of the earlier papers will have a hard time following. It would be useful to describe the model in the text. Likewise, the model parameters are listed (\"A~i~, Se~m~, etc.) without being explained. For more context, it might also be useful to relate their model more directly to the RL model in Daw et al. 2002 referenced in the paper, and also the model in Balasubramani et al. 2015, Frontiers of Computational Neuroscience.*

We agree that the model should have been presented with more details in the main text, instead of being confined to the Methods section. We have revised the model description in the Results section, which now appears as follows:

"The better performance observed in the escitalopram group could be underpinned by different mechanisms: alleviation of effort costs or inflation of incentive values, or both. \[...\] To capture all the effects, the cost-evidence accumulation model therefore necessitates five free parameters: the mean slope of cost-evidence accumulation (Se~m~) and its steepening for higher difficulty levels (Se~d~); the mean slope of cost-evidence dissipation during rest (Sr~m~) and its steepening for higher incentives (Sr~i~); and the expansion of the cost-evidence amplitude as higher incentives push the bounds back (A~i~)."

The referees also ask for a more detailed contextualization of our model, in particular with respect to the reinforcement learning framework (RL).

We would like to start by pointing important conceptual distinctions with respect to RL. First, RL deals with mapping stimuli to responses and outcomes across time. The parallel with our task is limited since here, external stimuli are mostly restricted to cues that have an explicit meaning (coins indicating the reward rate) and outcomes are deterministically and immediately coupled to actions: the cumulative payoff is displayed continuously as a function of the current force and incentive level. Second, the dynamics in RL reflects the learning of stimulus-response-outcome mapping across trials, whereas in our task, the dynamics reflects the allocation of effort within and between trials. Third, RL usually comes with a discretization of events into trials, with transient prediction errors whereas in our task, actions and feedback are continuous in time. Last, in RL, "cost" refers to negative outcomes that thereby vary along the same axis as "benefit" with a negative valence. In contrast, the effort cost is instrumental to get reward in our task. In total, the processes that we intended to model here do not involve much RL, as the mapping is clearly specified in the instructions. These processes are meant to solve a choice problem: knowing all the contingencies, how should I allocate my effort over time?

The referees also point to Balasubramani et al. 2015 who provide a detailed model for the implementation of RL in the basal ganglia, adding the notion of risk to standard RL. This level of detail is far beyond the sort of description that is needed to capture the behavior in our task. We acknowledge that the uncertainty about one\'s ability to sustain effort in the future could be seen as similar to the notion of risk defined as the variance in potential outcomes. However, such a link is extremely speculative for the moment.

Therefore, we prefer to avoid making a direct comparison to RL models. However, we intended to contextualize our model with respect to relevant notions that emerged in the field of RL, such as the notions of opponency, optimization, time scale and opportunity cost. We added the following paragraph in the Methods (with reference to Balasubramani et al., 2015):

"This computational model can be interpreted as follows, for a more complete discussion see (Meyniel 2013, 2014). The accumulation of cost evidence may reflect the build-up of physiological fatigue: the instantaneous effort cost increases as it becomes gradually more difficult to sustain a given force level. \[...\] This opportunity cost seems to be taken into account since the cost-evidence dissipation is speeded up for higher incentives (which is captured by Se~i~), so that effort can be resumed more quickly."

*B) More substantively, there were questions about the specificity of the effect from the modeling analyses. It is stated that interactions between treatments and pairs of computational variables (Se~m~ versus each other parameter) were always significant. The implication of this result depends on the sign of the parameters. The cumulative payoff effect might represent, for example, enhanced amplitude modulation (A~i~) and/or reduced cost-evidence accumulation (Se~m~). How were computational parameters coded when entered into the ANOVA? To assess specificity, one might want to reverse the coding for A and Sr. More generally, to what extent were the parameters independent of each other in the model? Also, might it be possible to define a different model space that would allow the use of Bayesian stats, and model comparison to estimate the drug effects on the various parameters? The distinct advantage of such an approach would be that it allows the capturing of drug effects despite the presence of individual differences of no interest.*

Parameters were entered in their native format in the ANOVA reported in the submitted manuscript. We agree that the direction of the effect matters. After flipping the sign of Se~m~, the interaction between variable types (Se~m~ vs. other variables) and groups (Placebo vs. Escitalopram) becomes:

Se~m~:A~i~ p=0.295

Se~m~:Se~d~ p\<0.001

Se~m~:Sr~m~ p=0.68

Se~m~:Sr~i~ p=0.27

However, flipping signs is rather post-hoc and motivated by seeing the actual results. Since this approach is questionable, we adopted, instead, a Bayesian model selection (BMS) approach. Indeed, as suggested by the reviewers, BMS may be more suited to address the issue of specificity, irrespective of the direction of changes induced by the treatment. We therefore replaced the paragraph with the ANOVA result by a model comparison.

In short, this comparison shows that there is a specific modulation of the latent parameters of cost-evidence accumulation by the SSRI treatment. Among single-modulation models, a modulation of Se~m~ outperforms modulation of any other parameter. Among double-modulation models, modulations of Se~m~ and Se~d~ outperform any other combination. These best models are also much better than a null model (without any modulation).

We replaced the paragraph with the ANOVA results by the following paragraph:

"To further test the specificity of SSRI effect on cost-evidence accumulation, we performed another Bayesian model selection that contrasted the two groups of subjects. \[\...\] A version with modulations of both Se~m~ and Se~d~ was slightly more likely than a version with only a modulation of Se~m~ (Δ=3) and much more likely than any other combination (Δ\>5.9)."

We added the [Table 3](#tbl3){ref-type="table"} to the revised manuscript.

We also added the following paragraph in the Methods section:

"Specificity of the treatment effect

We also used Bayesian model comparison to test the specificity of treatment effect on computational parameters. \[...\] All models were fitted with the variational Bayesian procedure by Daunizeau et al. 2014. Values of log model evidence are reported in [Table 3](#tbl3){ref-type="table"} for model comparison."

Regarding whether model parameters are independent from one another, the equation of the model suggests that they are not. For instance, the sensitivity of effort duration to incentives is controlled by the parameter A~i~ and scaled by Se~m~. However, the model is identifiable: for a given behavior, there is only one best-fitting set of parameter values. The critical issue for our pharmacological study is whether our model and fitting procedure can detect specific changes induced by the treatment. We quantified the specificity and sensitivity of our method with simulations ([Figure 2C](#fig2){ref-type="fig"}). We unpack this aspect further and the related paragraph now appears as:

"We checked the sensitivity and specificity of our model fitting procedure in detecting a treatment effect through simulations. A 20% change in any given parameter was reliably detected and the difference recovered by model fitting was significant in a 96% of simulations at least for A~i~, Se~m~, Sr~m~ and Sr~i~ and in a 77% of simulations for Se~d~. Importantly, a change in one single parameter was recovered without propagating to other parameters and the false alarm rate was below 5% for all parameters ([Figure 2C](#fig2){ref-type="fig"})."

*C) Is any background \'reference\' neuropsychological data available to confirm that there were no group differences of no interest? If so, please report.*

Indeed, participants were scored on psychometric scales. We included the following paragraph in the Methods:

"We also used psychological tests to assess differences between groups of subjects at baseline, before treatment. \[...\] Therefore, psychological variables were not significantly different at baseline when correcting for multiple comparisons (at p=0.05/9) and the one passing the uncorrected threshold p=0.05 was not significantly different during the testing phase."

*2) There were questions about the interpretation of the effects in terms of the role of time in task performance. The main effects coming out of the modeling analysis appear to be related to effort duration. But longer effort durations are also longer overall durations, which brings up the literature on 5-HT and delay costs (some of the delay discounting papers with 5-HT manipulations are actually cited in the manuscript). The authors appear to favor the view that different types of costs can be reduced to one process that is related overall to multiple types of costs. There is evidence both for and against this, and the authors are of course free to interpret their results in this way. In fact, this discussion contributes to the field in an interesting way. However, how much of the effect they are seeing is related to time per se? The authors should discuss this.*

We agree that time is an essential dimension in our task. However, the cost is about effort, not delay. This is because prolonging effort duration does not postpone reward delivery. Although the effect of SSRI accords well with the general idea that serotonin helps with overcoming cost, it cannot be explained by a change in temporal discounting. We intended to clarify our interpretation by adding the following paragraph to the Discussion:

"It is important to note that the SSRI effects obtained here relate to effort cost and not to time discounting. Although time is central in our task, it departs from delay and waiting paradigms in several respects. \[\...\]Therefore, the SSRI effect on effort duration (how long subjects sustain an effort) cannot be explained by a change in temporal discounting (how long subjects wait for a reward)."

*3) The Introduction might benefit from mentioning the implication of 5HT not just in apathy, but also in the other end of the motivation continuum, that is impulsivity. And in the Discussion, how do the findings relate to observations that 5HT is key for impulse control? More generally, the paper might come full circle, by linking, in the Discussion section, the obtained results to these various clinical hypotheses (involvement in apathy, impulsivity).*

We agree that impulsivity is a core concept in the literature on serotonin function. The Introduction implicitly referred to impulse control when quoting effects on behavioral inhibition and patience for delayed reward. We have now included this keyword in the text.

In the Discussion, we also integrated a reference to impulse control in the paragraph mentioning the effects of serotonin in waiting tasks. We also included a new paragraph to link our hypothesis and results to apathy and impulsivity:

"A general role for serotonin in cost processing also seems compatible with the effects on apathy and impulsivity reported in healthy and pathological conditions (Cools et al. 2005; Papakostas et al. 2006; Schweighofer et al. 2008; Crockett et al. 2009; Weber et al. 2009; Warden et al. 2012; Guitart-Masip et al. 2014; Miyazaki et al. 2014; Worbe et al. 2014). \[...\] As SSRIs might also reduce the perceived cost of delaying action, they would improve response control and reduce impulsivity (Cools et al. 2005, 2011; Crockett et al. 2009; Dayan 2012; Bari and Robbins 2013; Miyazaki et al. 2014; Fonseca et al. 2015)."

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

*The manuscript has been improved but there are some remaining issues that need to be addressed before acceptance, as outlined by the reviewer:*

*Reviewer \#4:*

*I have reviewed this paper from a statistical perspective as this is a registered trial.*

*This manuscript presents the analysis of a single randomised placebo controlled and double blinded study. It is not a trial of an intervention but rather a controlled study to understand the mechanism of action that the specific drug takes. The trial has been registered with a target sample size of 128 and it has a single hypothesis statement that aims to \'assess the effects of\' agolmelatine and escitalopram on emotional binding, emotional processing and motivation\'. Each participant is measured over several tasks during the treatment period of 9 weeks.*

*I realise that it is not in the eLife style to report numerical estimates in the Abstract but as this report analyses a single controlled experiment I think they should put the strength of the evidence in the Abstract to back up their statement that \'they show that serotonin also regulates other types of action costs such as effort\'. As there is no replication they should report this in a more guarded manner.*

We let the *eLife* editorial board decide whether this change is compatible with their style.

*The authors have completed the Consort statement but they need to provide more complete information within the manuscript so they can say yes to more of the checklist.*

We revised several aspects of the manuscript (see details below), which allowed us to check the following items of the Consort list: 7a, 8a, 9, 10, 14.

We also report the dates of the trial (item 14) in the section "Drug and Testing Schedule": "Data were collected between January 2012 and July 2013."

*The trial registration lists a compound aim/hypothesis and also lists three primary outcomes listed which I think have all been used in this analysis but the main question for the manuscript is \'does serotonin regulate the weight of effort cost as opposed to the weight of expected benefit?\'*

*I would like to see a clearer link between the main research question and the forms of analysis. A sample size of 58 is not that large even with repeated measurement. Was there really any power to test for interactions? The Consort checklist says \'no\' to sample size but surely the size was justified originally? I feel a bit concerned that sometimes Bonferonni correction is used to conclude there were no differences when this just reduces power.*

The trial registration lists three points. Point \#1 and \#2 are about tests on emotions performed by other research groups, not reported here. Point 3 lists goals for three "motivation" tasks, one being the Effort Allocation Task presented in this article, and the two others being probabilistic learning tasks that involved other researchers. Trial registration forms are highly stereotyped, and do not really fit the kind of exploratory trial that we participated in, with many tasks from various researchers. Therefore, our study addresses a much more specific question than the entire trial.

The sample size was proposed by the coordinators of the clinical trial, without formal calculation. This number seemed reasonable given typical studies in the field of cognitive neuroscience resorting to drugs in healthy subjects.

We added the following sentences in the Methods: "Given that the clinical trial was exploratory and also included tests from other research groups, the sample size was not selected specifically for our study; however, it appeared reasonable given typical studies in the field. Indeed, published between-subject comparisons of placebo and anti-depressant treatments were made on a lower sample size per group (e.g. N=14 in Harmer et al. 2014, N=20 in Chamberlain et al. 2006 and N=30 in Guitart-Masip et al. 2014), and a single visit per subject (while we have three)".

We modified the Consort checklist, checking the corresponding item (7a) and referring to the relevant page of the manuscript.

Regarding the Bonferonni correction, we believe that one must correct for multiple comparisons to take into account the unwanted inflation of type I error. To this end, we used a Bonferonni correction, which is the most conservative one. The reviewer suggests that a Bonferonni correction may be used to conveniently discard marginally significant effects of little interest. However, note that it imposes an equally stringent test for the effects of interest. In any case, we treated all effects equally, by reporting non-corrected significance levels, and when there were multiple comparisons, by highlighting which significance levels passed the Bonferonni-corrected threshold. We believe it is both transparent and statistically correct.

We nevertheless agree with the reviewer that a lack of power is an issue for marginally or non-significant results. We added the following sentence in the Discussion section, regarding the interaction with time that we could not detect: "... our study may lack the statistical power to reveal such an effect".

[^1]: These authors contributed equally to this work.
